查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1888750

尿失禁药物市场规模、份额和趋势分析报告：按类型、药物类别、性别、分销管道、地区和细分市场预测（2025-2033 年）

Urinary Incontinence Therapeutics Market Size, Share & Trends Analysis Report By Type (Stress Incontinence, Urge Incontinence), By Drug Class, By Gender, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

尿失禁药物市场摘要

2024年全球尿失禁药物市场规模估计为43.2亿美元，预计2033年将达到69.5亿美元。

预计从 2025 年到 2033 年，该行业将以 5.4% 的复合年增长率成长。这一增长主要受老年人口中尿失禁盛行率上升以及对有效治疗性介入的需求不断增长的推动。

根据 Dovepress 2023 年 5 月发布的报告，女性尿失禁的盛行率为 24.8%，其中 12.7% 为应力性尿失禁，8.0% 为混合性尿失禁，4.1% 为急性尿失禁。研究表明，患病率随年龄和体重指数 (BMI) 的增加而逐渐升高，凸显了早期诊断和有效治疗的必要性。患者和医护人员对尿失禁的意识提升，改善了诊断和治疗率，从而促进了治疗的普及。 β3 肾上腺素受体促效剂和抗胆碱能药物的进步改善了不同患者群体的治疗效果，而口服药物和非侵入性治疗方法的普及提高了患者的用药依从性。不断扩展的零售和线上药局网路确保了稳定的药品供应，并增强了各地区的市场表现。

随着製药公司致力于开发标靶性强、安全性高的治疗方法以满足持续存在的未满足医疗需求，市场正在不断扩大。例如，2024年4月，Lupin公司在美国推出了用于治疗膀胱过动症的学名药药Mirabegron（Mirbetriq的仿製药）。此类学名药的出现以及新型作用机制的创新，丰富了治疗选择，提高了药物的可及性。对旨在提高疗效和减少副作用的研究项目的投入，为开发差异化治疗方法创造了机会。品牌药和学名药并存，确保了成本的柔软性，并有助于提高患者的治疗依从性。主要企业与研究机构之间的策略合作，正在加速药物研发进程，并拓展治疗产品线。持续的生命週期管理和核准后监测，强化了产品定位，维持了长期竞争力和收入稳定性。

已开发地区和新兴地区医疗保健支出的成长，以及泌尿系统和妇科医疗服务可近性的提高，进一步推动了市场扩张。例如，根据截至2025年10月的全球数据，预计60岁及以上人口将从2020年的10亿增加到2050年的21亿，翻倍。随着人口的增长，尿失禁及相关老年疾病的负担预计将会增加，从而推动对有效且易于获得的治疗方法的需求。医疗保健提供者正透过改善疾病管理来优先考虑老年人的生活质量，这推动了治疗策略的创新。药物传递技术的进步提高了治疗的精准性和便捷性，而针对膀胱过动症和混合性尿失禁的临床研究的不断深入，则推动了联合治疗的开发。持续的创新、高效的分销系统以及不断增长的临床应用预计将支持尿失禁治疗市场在整个预测期内保持稳定的成长势头。

目录

第一章调查方法和范围

第二章执行摘要

第三章 尿失禁药物市场变数、趋势与范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 尿失禁药物市场：按类型分類的业务分析

  • 按类型分類的市场份额（2024 年和 2033 年）
  • 市场规模、预测与趋势分析（按类型划分，2021年至2033年）
  • 应力性尿失禁
  • 急性尿失禁
  • 溢出性尿失禁
  • 功能性尿失禁
  • 其他类型

5. 尿失禁药物市场：依药物类别分類的业务分析

  • 按药物类别分類的市场份额（2024 年和 2033 年）
  • 市场规模、预测和趋势分析（按药物类别划分，2021-2033 年）
  • 抗胆碱能药物
  • β3-肾上腺素受体促效剂
  • α受体阻断剂
  • 雌激素
  • 去氨加压素
  • 三环抗忧郁药物
  • 其他药物类别

6. 尿失禁药物市场：性别业务分析

  • 按性别分類的市场份额（2024 年和 2033 年）
  • 市场规模、预测与趋势分析（按性别划分，2021-2033 年）
  • 男性
  • 女士

7. 尿失禁药物市场：按分销管道分類的业务分析

  • 按分销管道分類的市场份额（2024 年和 2033 年）
  • 市场规模、预测与趋势分析（按分销管道划分，2021-2033 年）
  • 医院药房
  • 零售药房
  • 网路药房

第八章 尿失禁药物市场：区域估算与趋势分析

  • 区域市场占有率分析（2024 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析（按地区划分，2021-2033 年）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Pfizer Inc.
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Johnson &Johnson
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi SA
    • GlaxoSmithKline plc
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Bayer AG
    • Ferring Pharmaceuticals
Product Code: GVR-4-68040-366-2

Urinary Incontinence Therapeutics Market Summary

The global urinary incontinence therapeutics market size was estimated at USD 4.32 billion in 2024 and is projected to reach USD 6.95 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. This growth is primarily driven by the increasing prevalence of urinary incontinence among aging populations and the growing demand for effective therapeutic interventions that address bladder dysfunction.

According to a May 2023 report by Dovepress, the prevalence of female urinary incontinence was found to be 24.8%, with stress incontinence accounting for 12.7%, mixed incontinence for 8.0%, and urgency incontinence for 4.1%. The study indicated that prevalence increased progressively with age and body mass index, emphasizing the need for early diagnosis and effective therapy. Rising awareness among patients and healthcare providers has improved diagnosis and management rates, supporting higher treatment adoption. Advancements in B3-adrenoceptor agonists and antimuscarinic agents are improving outcomes across patient groups, while wider access to oral and non-invasive options is enhancing adherence. Expanding retail and online pharmacy networks are ensuring consistent medication availability, reinforcing market performance across regions.

The market is expanding as pharmaceutical companies focus on developing targeted and safer therapies addressing persistent unmet needs. For instance, in April 2024, Lupin Ltd introduced Mirabegron, a generic alternative to Myrbetriq, aimed at managing overactive bladder in the U.S. The introduction of such generics and novel mechanisms of action is diversifying treatment options and improving accessibility. Investments in research programs to enhance efficacy and minimize side effects are creating opportunities for the development of differentiated therapies. The presence of branded and generic drugs ensures cost flexibility, improving treatment compliance. Strategic collaborations between leading players and research organizations are accelerating development timelines and expanding the therapeutic pipeline. Continuous lifecycle management and post-approval studies are reinforcing product positioning, sustaining long-term competitiveness, and revenue stability.

Market expansion is further supported by rising healthcare expenditures and increasing access to urology and women's health services across both developed and emerging regions. For instance, in October 2025, global data showed that the number of people aged 60 and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. As this population segment grows, the burden of urinary incontinence and related geriatric conditions is expected to rise, driving demand for effective and accessible treatment options. Healthcare providers are prioritizing the quality of life of older adults through improved disease management, which is stimulating innovation in therapeutic strategies. Advancements in drug delivery technologies are improving treatment precision and convenience, while expanded clinical research in overactive bladder and mixed incontinence is driving the evolution of combination regimens. Sustained innovation, efficient distribution systems, and growing clinical adoption are expected to maintain a stable growth trajectory for the urinary incontinence therapeutics market through the forecast period.

Global Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global urinary incontinence therapeutics market report based on type, drug class, gender, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Stress Incontinence
  • Urge Incontinence
  • Overflow Incontinence
  • Functional Incontinence
  • Other Types
  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants
  • Other Drug Classes
  • Gender Outlook (Revenue, USD Million, 2021 - 2033)
  • Male
  • Female
  • Distribution ChannelOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Gender
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Urinary Incontinence Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Urinary Incontinence Therapeutics Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Stress Incontinence
    • 4.4.1. Stress Incontinence Market, 2021 - 2033 (USD Million)
  • 4.5. Urge Incontinence
    • 4.5.1. Urge Incontinence Market, 2021 - 2033 (USD Million)
  • 4.6. Overflow Incontinence
    • 4.6.1. Overflow Incontinence Market, 2021 - 2033 (USD Million)
  • 4.7. Functional Incontinence
    • 4.7.1. Functional Incontinence Market, 2021 - 2033 (USD Million)
  • 4.8. Other Types
    • 4.8.1. Other Types Market, 2021 - 2033 (USD Million)

Chapter 5. Urinary Incontinence Therapeutics Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2033
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 5.4. Anticholinergics
    • 5.4.1. Anticholinergics Market, 2021 - 2033 (USD Million)
  • 5.5. Beta-3 Adrenoceptor Agonists
    • 5.5.1. Beta-3 Adrenoceptor Agonists Market, 2021 - 2033 (USD Million)
  • 5.6. Alpha Blockers
    • 5.6.1. Alpha Blockers Market, 2021 - 2033 (USD Million)
  • 5.7. Estrogen
    • 5.7.1. Estrogen Market, 2021 - 2033 (USD Million)
  • 5.8. Desmopressin
    • 5.8.1. Desmopressin Market, 2021 - 2033 (USD Million)
  • 5.9. Tricyclic Antidepressants
    • 5.9.1. Tricyclic Antidepressants Market, 2021 - 2033 (USD Million)
  • 5.10. Other Drug Classes
    • 5.10.1. Other Drug Classes Market, 2021 - 2033 (USD Million)

Chapter 6. Urinary Incontinence Therapeutics Market: Gender Business Analysis

  • 6.1. Gender Market Share, 2024 & 2033
  • 6.2. Gender Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by gender, 2021 to 2033 (USD Million)
  • 6.4. Male
    • 6.4.1. Male Market, 2021 - 2033 (USD Million)
  • 6.5. Female
    • 6.5.1. Female Market, 2021 - 2033 (USD Million)

Chapter 7. Urinary Incontinence Therapeutics Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 8. Urinary Incontinence Therapeutics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Urinary Incontinence Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Gender Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Gender Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Gender Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Gender Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Gender Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Gender Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Gender Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Gender Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Gender Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Gender Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Gender Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Gender Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Gender Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Gender Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Gender Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Gender Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Gender Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Gender Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Gender Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Gender Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Gender Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Gender Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Gender Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. AbbVie Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Astellas Pharma Inc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Johnson & Johnson
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Viatris Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Teva Pharmaceutical Industries Ltd.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Sanofi S.A.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. GlaxoSmithKline plc
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Bayer AG
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Ferring Pharmaceuticals
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global urinary incontinence therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 6 Global urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 7 Global urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 8 North America urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 10 North America urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 11 North America urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 12 North America urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 U.S urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 14 U.S urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 15 U.S urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 16 U.S urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Canada urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 18 Canada urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 19 Canada urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 20 Canada urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 21 Mexico urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 22 Mexico urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 23 Mexico urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 24 Mexico urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 Europe urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 27 Europe urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 28 Europe urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 29 Europe urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 UK urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 31 UK urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 32 UK urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 33 UK urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Germany urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 35 Germany urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 36 Germany urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 37 Germany urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 38 France urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 39 France urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 40 France urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 41 France urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Italy urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 43 Italy urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 44 Italy urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 45 Italy urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46 Spain urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 47 Spain urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 48 Spain urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 49 Spain urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 50 Norway urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 51 Norway urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 52 Norway urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 53 Norway urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Denmark urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 55 Denmark urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 56 Denmark urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 57 Denmark urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 Sweden urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 59 Sweden urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 60 Sweden urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 61 Sweden urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific urinary incontinence therapeutics market, by drug class, 2021-2033, (USD
  • Table 65 Asia Pacific urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Japan urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 68 Japan urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 69 Japan urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 70 Japan urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71 China urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 72 China urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 73 China urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 74 China urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 India urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 76 India urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 77 India urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 78 India urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 79 Australia urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 80 Australia urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 81 Australia urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 82 Australia urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 83 South Korea urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 84 South Korea urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 85 South Korea urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 86 South Korea urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Thailand urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 88 Thailand urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 89 Thailand urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 90 Thailand urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 91 Latin America urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 93 Latin America urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 94 Latin America urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 95 Latin America urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 96 Brazil urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 97 Brazil urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 98 Brazil urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 99 Brazil urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 100 Argentina urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 101 Argentina urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 102 Argentina urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 103 Argentina urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa Urinary incontinence therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 108 Middle East & Africa urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 109 South Africa urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 110 South Africa urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 111 South Africa urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 112 South Africa urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 117 UAE urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 118 UAE urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 119 UAE urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 120 UAE urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 121 Kuwait urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 123 Kuwait urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 124 Kuwait urinary incontinence therapeutics market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Urinary incontinence therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Urinary incontinence therapeutics market dynamics
  • Fig. 11 Urinary incontinence therapeutics market: Porter's five forces analysis
  • Fig. 12 Urinary incontinence therapeutics market: PESTLE analysis
  • Fig. 13 Type market, 2021 - 2033 (USD Million)
  • Fig. 14 Stress Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 15 Urge Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 16 Overflow Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 17 Functional Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 18 Other Types market, 2021 - 2033 (USD Million)
  • Fig. 19 Drug Class market, 2021 - 2033 (USD Million)
  • Fig. 20 Anticholinergics market, 2021 - 2033 (USD Million)
  • Fig. 21 Beta-3 Adrenoceptor Agonists market, 2021 - 2033 (USD Million)
  • Fig. 22 Alpha Blockers market, 2021 - 2033 (USD Million)
  • Fig. 23 Estrogen market, 2021 - 2033 (USD Million)
  • Fig. 24 Desmopressin market, 2021 - 2033 (USD Million)
  • Fig. 25 Tricyclic Antidepressants market, 2021 - 2033 (USD Million)
  • Fig. 26 Other Drug Classes market, 2021 - 2033 (USD Million)
  • Fig. 27 Gender market, 2021 - 2033 (USD Million)
  • Fig. 28 Male market, 2021 - 2033 (USD Million)
  • Fig. 29 Female market, 2021 - 2033 (USD Million)
  • Fig. 30 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 31 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 32 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 33 Online Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 34 Urinary incontinence therapeutics market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Europe urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Asia Pacific urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 73 Latin America urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 Middle East & Africa urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait urinary incontinence therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis
  • Fig. 89 Strategic framework